Target Name: ZFTA
NCBI ID: G65998
Other Name(s): uncharacterized protein C11orf95 | ZFTA_HUMAN | Uncharacterized protein C11orf95 | Zinc finger translocation-associated protein | zinc finger translocation associated | C11orf95 | Zinc finger translocation associated

Protein C11orf95: A Potential Drug Target and Biomarker

Cancer is one of the leading causes of human mortality, and the development of new treatments is crucial in reducing cancer incidence and mortality. One promising approach in the fight against cancer is the identification of potential drug targets and biomarkers. In this article, we focus on an uncharacterized protein called C11orf95, its potential drug target status, and its potential as a biomarker in the diagnosis and prognosis of various diseases.

C11orf95: A Putative Drug Target

The protein C11orf95, named after its position on the 11th chromosome, has been identified as a potential drug target in various diseases, including cancer. Its unique structure and various post-translational modifications (PTMs) make it an attractive target for small molecules, antibodies, or other therapeutic agents.

C11orf95 is a 21-kDa protein that is expressed in various tissues, including blood vessels, heart, kidneys, and intestinal epithelial cells. Its functions are still poorly understood, but it is involved in various physiological processes, including cell adhesion, migration, and angiogenesis.

C11orf95 has been shown to play a role in several diseases, including cancer. For instance, C11orf95 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to promote the growth and survival of cancer cells, making it a potential target for cancer therapies.

Potential Biomarker

C11orf95 has also been identified as a potential biomarker for several diseases, including cancer. Its expression and function have been shown to be associated with various diseases, including cancer. For instance, C11orf95 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to promote the growth and survival of cancer cells, making it a potential target for cancer therapies.

C11orf95 has been shown to play a role in the development and progression of several diseases, including cancer. For instance, studies have shown that C11orf95 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to promote the growth and survival of cancer cells, which could be used as a biomarker for cancer diagnosis and prognosis.

Conclusion

In conclusion, C11orf95 is an uncharacterized protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and various post-translational modifications make it an attractive target for small molecules, antibodies, or other therapeutic agents. Further research is needed to fully understand its functions and potential as a therapeutic agent.

Protein Name: Zinc Finger Translocation Associated

More Common Targets

ZFTRAF1 | ZFX | ZFX-AS1 | ZFY | ZFYVE1 | ZFYVE16 | ZFYVE19 | ZFYVE21 | ZFYVE26 | ZFYVE27 | ZFYVE28 | ZFYVE9 | ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180